RSV and HMPV vaccine study for adults 60 and older
Part of Infections clinical trials.
This study tests a new vaccine that targets two respiratory viruses, RSV and HMPV, to see if it's safe and effective in adults 60 years and older. It may help prevent serious lung infections caused by these viruses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older.
- You cannot become pregnant (for women, this means at least one year past menopause or surgically sterile).
- You have not had a lab-confirmed RSV or HMPV infection in the last 12 months, and no one in your house has had one either.
- You have never had a heart muscle or heart lining inflammation condition (myocarditis, pericarditis, or myopericarditis).
- You have not received any other RSV or HMPV vaccine before, and no mRNA vaccine in the last 2 months.
- You have not had Guillain-Barré Syndrome or a blood transfusion in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine that may protect against two common viruses that cause breathing problems, RSV and hMPV. It is for healthy younger adults (18-49) and older adults (60-80) to see if the vaccine is safe and works well.
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
This study tests a new RSV vaccine to see if it is safe for healthy adults. It uses mRNA technology to help your body build protection against RSV, a common respiratory virus.
Hear when a new Respiratory Syncytial Virus Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.